Abstract OBJECTIVE: To investigate the correlation between the ratio of serum vascular endothelial growth factor (VEGF)/endostatin (ES) and childhood acute leukemia(AL). METHODS: Serum levels of VEGF and ES were measured using ELISA in 35 children with acute AL before and after chemotherapy. The ratio of VEGF/ES was calculated. Thirty healthy children served as the control group. RESULTS: The serum levels of VEGF (196±66 pg/mL vs 29±10 pg/mL) and ES (35±7 ng/mL vs 19±4 ng/mL) in the AL group before chemotherapy were significantly higher than those in the control group (P<0.01). The ratio of VEGF/ES in the AL group before chemotherapy was significantly higher than that in the control group (6.7±3.0 vs 1.6±0.7; P<0.01). In 20 children with AL who achieved complete remission, the serum levels of VEGF and ES and the VEGF/ES ratio were reduced after chemotherapy (83±35 pg/mL, 27±5 ng/mL, 3.1±1.3, respectively; P<0.01), although the serum levels of VEGF and ES were still higher than those in the control group (P<0.01). The VEGF/ES ratio in CR patients was not significantly different from that in the control group. The serum levels of VEGF (r=0.301, P=0.045) and the VEGF/ES ratio (r=0.411, P=0.015) were positively correlated with the count of blast cells in juvenile bone marrow in 35 children with AL before chemotherapy. CONCLUSIONS: Serum VEGF and ES levels are associated with the development of childhood AL. The VEGF/ES ratio can be used to evaluate the disease progression in children with AL.
GU Jiao-Wei,HU Zhong-Dong,LIU Zhuang. Correlation between the ratio of serum vascular endothelial growth factor/endostatin and childhood acute leukemia[J]. 中国当代儿科杂志, 2011, 13(6): 475-477.
GU Jiao-Wei,HU Zhong-Dong,LIU Zhuang. Correlation between the ratio of serum vascular endothelial growth factor/endostatin and childhood acute leukemia[J]. CJCP, 2011, 13(6): 475-477.
［3］Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemia and myelodysplastic syndrome［J］. Blood, 2000, 96(6): 2240-2245.
［6］Folkman J. Tumor angiogenesis: therapeutic implications［J］. N Engl J Med, 1971, 285(16): 1182-1186.
［7］Folkman J.Role of angiogenesis in tumor growth and metastasis ［J］. Semin Oncol, 2002, 29(6): 15-18.
［8］Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia ［J］. Am J Pathol, 1997, 150 (3): 815-821.
［9］Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes［J］. Blood, 2001, 97(5): 1427-1434.
［10］Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, et al. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antiboby directed against vascular endothelial growth factor receptor-2［J］. Leuk Lymphoma, 2004, 45(9): 1887-1897.
［11］Fiedler W, Graeven U, Ergün S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myloid leukemia［J］. Blood, 1997, 89(6): 1870-1875.
［12］Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis［J］.J Biol Chem, 1999, 274(17): 11721-11726.
［13］Chavakis E, Dimrneler S. Regulation of endothelial cell survival and apoptosis during angiogenesis［J］. Arterioscler Thromb Vasc Biol, 2002, 22(6):887-893.
［14］Chang Z, Choon A, Friedl A. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growh factor-2 binding［J］. Am J Pathol, 1999, 155(1):71-76.
［15］Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, et al. Endostatin induced tyrosine kinase signaling Through the Shb adaptor protein regulates endothelial cell apoptosis［J］. Blood, 2000, 95(11): 3403-3411.
［16］Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, et al. Endostatin inhibits the vascular endothelial growth factor induced mobilization of endothelial progenitor cells［J］. Cancer Research, 2003, 63(12): 8345-8350.
［17］Iversen PO, Sorensen DR, Benestad HB. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias［J］. Leukemia, 2002, 16(3): 376-381.
［18］Aref S, El-Sherbiny M, Azmy E, Goda T, Selim T, El-Refaie M, et al. Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia［J］. Hematology, 2008, 13(2): 95-100.
